BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee JS, Thorgeirsson SS. Comparative and integrative functional genomics of HCC. Oncogene 2006;25:3801-9. [PMID: 16799621 DOI: 10.1038/sj.onc.1209561] [Cited by in Crossref: 78] [Cited by in F6Publishing: 81] [Article Influence: 4.9] [Reference Citation Analysis]
Number Citing Articles
1 Paoloni M, Davis S, Lana S, Withrow S, Sangiorgi L, Picci P, Hewitt S, Triche T, Meltzer P, Khanna C. Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics 2009;10:625. [PMID: 20028558 DOI: 10.1186/1471-2164-10-625] [Cited by in Crossref: 169] [Cited by in F6Publishing: 157] [Article Influence: 13.0] [Reference Citation Analysis]
2 Buendia MA. Tumor suppressors in hepatocellular carcinoma: many are called, but few are chosen. J Hepatol 2007;46:546-8. [PMID: 17313992 DOI: 10.1016/j.jhep.2007.01.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
3 Marquardt JU, Fischer K, Baus K, Kashyap A, Ma S, Krupp M, Linke M, Teufel A, Zechner U, Strand D, Thorgeirsson SS, Galle PR, Strand S. Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients. Hepatology 2013;58:1054-64. [PMID: 23526469 DOI: 10.1002/hep.26413] [Cited by in Crossref: 94] [Cited by in F6Publishing: 91] [Article Influence: 10.4] [Reference Citation Analysis]
4 Yang H, He X, Song Q, Chen M, Li J, Wang M, Yu J, Yao J, Liu L, Lin J. Association of Ephrin receptor A3 gene polymorphism with susceptibility to chronic severe hepatitis B: EphA3 polymorphism and HBV infection. Hepatology Research 2012;42:790-7. [DOI: 10.1111/j.1872-034x.2012.00977.x] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
5 Thompson SM, Callstrom MR, Knudsen B, Anderson JL, Carter RE, Grande JP, Roberts LR, Woodrum DA. Development and preliminary testing of a translational model of hepatocellular carcinoma for MR imaging and interventional oncologic investigations. J Vasc Interv Radiol 2012;23:385-95. [PMID: 22265247 DOI: 10.1016/j.jvir.2011.11.018] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
6 Ju H, Han K, Lee JD, Ro SW. Transgenic mouse models generated by hydrodynamic transfection for genetic studies of liver cancer and preclinical testing of anti-cancer therapy: Transgenic mouse models generated by hydrodynamic transfection. Int J Cancer 2016;138:1601-8. [DOI: 10.1002/ijc.29703] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
7 Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, Dienes HP, Odenthal M. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology. 2008;47:1223-1232. [PMID: 18307259 DOI: 10.1002/hep.22158] [Cited by in Crossref: 312] [Cited by in F6Publishing: 317] [Article Influence: 22.3] [Reference Citation Analysis]
8 Liu Z, Ma Y, Yang J, Qin H. Upregulated and Downregulated Proteins in Hepatocellular Carcinoma: A Systematic Review of Proteomic Profiling Studies. OMICS: A Journal of Integrative Biology 2011;15:61-71. [DOI: 10.1089/omi.2010.0061] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
9 Zhu Q, Sun Y, Zhou Q, He Q, Qian H. Identification of key genes and pathways by bioinformatics analysis with TCGA RNA sequencing data in hepatocellular carcinoma. Mol Clin Oncol 2018;9:597-606. [PMID: 30546887 DOI: 10.3892/mco.2018.1728] [Cited by in Crossref: 7] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
10 Qu JH, Chang XJ, Lu YY, Bai WL, Chen Y, Zhou L, Zeng Z, Wang CP, An LJ, Hao LY, Xu GL, Gao XD, Lou M, Lv JY, Yang YP. Overexpression of metastasis-associated in colon cancer 1 predicts a poor outcome of hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol 2012; 18(23): 2995-3003 [PMID: 22736924 DOI: 10.3748/wjg.v18.i23.2995] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
11 Berasain C, Castillo J, Prieto J, Avila MA. New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system. Liver Int 2007;27:174-85. [PMID: 17311611 DOI: 10.1111/j.1478-3231.2006.01424.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 3.3] [Reference Citation Analysis]
12 Lee NP, Cheung ST, Poon RT, Fan ST, Luk JM. Genomic and proteomic biomarkers for diagnosis and prognosis of hepatocellular carcinoma. Biomark Med 2007;1:273-84. [PMID: 20477402 DOI: 10.2217/17520363.1.2.273] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
13 Thompson SM, Callstrom MR, Knudsen B, Anderson JL, Butters KA, Grande JP, Roberts LR, Woodrum DA. AS30D model of hepatocellular carcinoma: tumorigenicity and preliminary characterization by imaging, histopathology, and immunohistochemistry. Cardiovasc Intervent Radiol 2013;36:198-203. [PMID: 22923329 DOI: 10.1007/s00270-012-0466-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
14 Pang RWC, Joh JW, Johnson PJ, Monden M, Pawlik TM, Poon RTP. Biology of Hepatocellular Carcinoma. Ann Surg Oncol 2008;15:962-71. [DOI: 10.1245/s10434-007-9730-z] [Cited by in Crossref: 122] [Cited by in F6Publishing: 118] [Article Influence: 8.7] [Reference Citation Analysis]
15 Buchkremer S, Hendel J, Krupp M, Weinmann A, Schlamp K, Maass T, Staib F, Galle PR, Teufel A. Library of molecular associations: curating the complex molecular basis of liver diseases. BMC Genomics 2010;11:189. [PMID: 20302666 DOI: 10.1186/1471-2164-11-189] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
16 Pancoska P, Carr BI, Branch RA. Network-based analysis of survival for unresectable hepatocellular carcinoma. Semin Oncol 2010;37:170-81. [PMID: 20494709 DOI: 10.1053/j.seminoncol.2010.03.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
17 Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, Ma B, Zender P, Kubicka S, Luk JM, Schirmacher P, McCombie WR, Wigler M, Hicks J, Hannon GJ, Powers S, Lowe SW. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 2008;135:852-64. [PMID: 19012953 DOI: 10.1016/j.cell.2008.09.061] [Cited by in Crossref: 328] [Cited by in F6Publishing: 313] [Article Influence: 23.4] [Reference Citation Analysis]
18 Yan H, Wang S, Yu H, Zhu J, Chen C. Molecular pathways and functional analysis of miRNA expression associated with paclitaxel-induced apoptosis in hepatocellular carcinoma cells. Pharmacology 2013;92:167-74. [PMID: 24060847 DOI: 10.1159/000354585] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
19 Neuveut C, Wei Y, Buendia MA. Mechanisms of HBV-related hepatocarcinogenesis. J Hepatol. 2010;52:594-604. [PMID: 20185200 DOI: 10.1016/j.jhep.2009.10.033] [Cited by in Crossref: 259] [Cited by in F6Publishing: 264] [Article Influence: 21.6] [Reference Citation Analysis]
20 Frenette C, Gish RG. Hepatocellular carcinoma: molecular and genomic guideline for the clinician. Clin Liver Dis 2011;15:307-21, vii-x. [PMID: 21689615 DOI: 10.1016/j.cld.2011.03.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
21 Fernández M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. J Hepatol. 2009;50:604-620. [PMID: 19157625 DOI: 10.1016/j.jhep.2008.12.011] [Cited by in Crossref: 381] [Cited by in F6Publishing: 361] [Article Influence: 27.2] [Reference Citation Analysis]
22 Kadara H, Fujimoto J, Men T, Ye X, Lotan D, Lee JS, Lotan R. A Gprc5a tumor suppressor loss of expression signature is conserved, prevalent, and associated with survival in human lung adenocarcinomas. Neoplasia 2010;12:499-505. [PMID: 20563252 DOI: 10.1593/neo.10390] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
23 Coban Z, Barton MC. Integrative genomics: liver regeneration and hepatocellular carcinoma. J Cell Biochem 2012;113:2179-84. [PMID: 22345090 DOI: 10.1002/jcb.24104] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
24 Nasri B, Inokuchi M, Ishikawa T, Uetake H, Takagi Y, Otsuki S, Kojima K, Kawano T. High expression of EphA3 (erythropoietin-producing hepatocellular A3) in gastric cancer is associated with metastasis and poor survival. BMC Clin Pathol 2017;17:8. [PMID: 28465671 DOI: 10.1186/s12907-017-0047-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
25 Frau M, Feo F, Pascale RM. Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis. J Hepatol. 2013;59:830-841. [PMID: 23665184 DOI: 10.1016/j.jhep.2013.04.031] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 7.8] [Reference Citation Analysis]
26 Pogribny IP, Tryndyak VP, Boyko A, Rodriguez-Juarez R, Beland FA, Kovalchuk O. Induction of microRNAome deregulation in rat liver by long-term tamoxifen exposure. Mutat Res. 2007;619:30-37. [PMID: 17343880 DOI: 10.1016/j.mrfmmm.2006.12.006] [Cited by in Crossref: 102] [Cited by in F6Publishing: 98] [Article Influence: 6.8] [Reference Citation Analysis]
27 Laparra J, Fotschki B, Haros C. Immunonutritional consequences of different serine-type protease inhibitors in a C57BL/6 hepatocarcinoma model. Oncotarget 2019;10:760-72. [PMID: 30774778 DOI: 10.18632/oncotarget.26605] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
28 Abdalla MA, Haj-Ahmad Y. Promising Candidate Urinary MicroRNA Biomarkers for the Early Detection of Hepatocellular Carcinoma among High-Risk Hepatitis C Virus Egyptian Patients. J Cancer. 2012;3:19-31. [PMID: 22211142 DOI: 10.7150/jca.3.19] [Cited by in Crossref: 80] [Cited by in F6Publishing: 79] [Article Influence: 7.3] [Reference Citation Analysis]
29 Maass T, Sfakianakis I, Staib F, Krupp M, Galle PR, Teufel A. Microarray-based gene expression analysis of hepatocellular carcinoma. Curr Genomics. 2010;11:261-268. [PMID: 21119890 DOI: 10.2174/138920210791233063] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
30 Colak D, Chishti MA, Al-Bakheet AB, Al-Qahtani A, Shoukri MM, Goyns MH, Ozand PT, Quackenbush J, Park BH, Kaya N. Integrative and comparative genomics analysis of early hepatocellular carcinoma differentiated from liver regeneration in young and old. Mol Cancer. 2010;9:146. [PMID: 20540791 DOI: 10.1186/1476-4598-9-146] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
31 Ivanovska I, Zhang C, Liu AM, Wong KF, Lee NP, Lewis P, Philippar U, Bansal D, Buser C, Scott M, Mao M, Poon RT, Fan ST, Cleary MA, Luk JM, Dai H. Gene signatures derived from a c-MET-driven liver cancer mouse model predict survival of patients with hepatocellular carcinoma. PLoS One 2011;6:e24582. [PMID: 21949730 DOI: 10.1371/journal.pone.0024582] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
32 Bengochea A, de Souza MM, Lefrançois L, Le Roux E, Galy O, Chemin I, Kim M, Wands JR, Trepo C, Hainaut P. Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. Br J Cancer. 2008;99:143-150. [PMID: 18577996 DOI: 10.1038/sj.bjc.6604422] [Cited by in Crossref: 136] [Cited by in F6Publishing: 134] [Article Influence: 9.7] [Reference Citation Analysis]
33 Fan Y, Boivin GP, Knudsen ES, Nebert DW, Xia Y, Puga A. The aryl hydrocarbon receptor functions as a tumor suppressor of liver carcinogenesis. Cancer Res 2010;70:212-20. [PMID: 19996281 DOI: 10.1158/0008-5472.CAN-09-3090] [Cited by in Crossref: 117] [Cited by in F6Publishing: 70] [Article Influence: 9.0] [Reference Citation Analysis]
34 Winkler J, Ori A, Holzer K, Sticht C, Dauch D, Eiteneuer EM, Pinna F, Geffers R, Ehemann V, Andres-pons A, Breuhahn K, Longerich T, Bermejo JL, Gretz N, Zender L, Schirmacher P, Beck M, Singer S. Prosurvival function of the cellular apoptosis susceptibility/importin-α1 transport cycle is repressed by p53 in liver cancer: Winkler et al. Hepatology 2014;60:884-95. [DOI: 10.1002/hep.27207] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
35 Andersen JB, Loi R, Perra A, Factor VM, Ledda-Columbano GM, Columbano A, Thorgeirsson SS. Progenitor-derived hepatocellular carcinoma model in the rat. Hepatology. 2010;51:1401-1409. [PMID: 20054870 DOI: 10.1002/hep.23488] [Cited by in Crossref: 95] [Cited by in F6Publishing: 99] [Article Influence: 7.9] [Reference Citation Analysis]
36 Thillai K, Ross P, Sarker D. Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis? World J Gastrointest Oncol 2016; 8(2): 173-185 [PMID: 26909132 DOI: 10.4251/wjgo.v8.i2.173] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
37 Fernando J, Malfettone A, Cepeda EB, Vilarrasa-Blasi R, Bertran E, Raimondi G, Fabra À, Alvarez-Barrientos A, Fernández-Salguero P, Fernández-Rodríguez CM. A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells. Int J Cancer. 2015;136:E161-E172. [PMID: 25053293 DOI: 10.1002/ijc.29097] [Cited by in Crossref: 70] [Cited by in F6Publishing: 67] [Article Influence: 8.8] [Reference Citation Analysis]
38 Nevzorova YA, Hu W, Cubero FJ, Haas U, Freimuth J, Tacke F, Trautwein C, Liedtke C. Overexpression of c-myc in hepatocytes promotes activation of hepatic stellate cells and facilitates the onset of liver fibrosis. Biochim Biophys Acta. 2013;1832:1765-1775. [PMID: 23770341 DOI: 10.1016/j.bbadis.2013.06.001] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 4.9] [Reference Citation Analysis]
39 Viatour P, Ehmer U, Saddic LA, Dorrell C, Andersen JB, Lin C, Zmoos AF, Mazur PK, Schaffer BE, Ostermeier A, Vogel H, Sylvester KG, Thorgeirsson SS, Grompe M, Sage J. Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J Exp Med. 2011;208:1963-1976. [PMID: 21875955 DOI: 10.1084/jem.20110198] [Cited by in Crossref: 137] [Cited by in F6Publishing: 129] [Article Influence: 12.5] [Reference Citation Analysis]
40 Dufour JF, Johnson P. Liver cancer: from molecular pathogenesis to new therapies: summary of the EASL single topic conference. J Hepatol 2010;52:296-304. [PMID: 20006399 DOI: 10.1016/j.jhep.2009.11.010] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
41 Latasa MU, Salis F, Urtasun R, Garcia-Irigoyen O, Elizalde M, Uriarte I, Santamaria M, Feo F, Pascale RM, Prieto J, Berasain C, Avila MA. Regulation of amphiregulin gene expression by β-catenin signaling in human hepatocellular carcinoma cells: a novel crosstalk between FGF19 and the EGFR system. PLoS One 2012;7:e52711. [PMID: 23285165 DOI: 10.1371/journal.pone.0052711] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 3.6] [Reference Citation Analysis]
42 Li S, Fu H, Wang Y, Tie Y, Xing R, Zhu J, Sun Z, Wei L, Zheng X. MicroRNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene in human hepatocellular carcinoma. Hepatology. 2009;49:1194-1202. [PMID: 19133651 DOI: 10.1002/hep.22757] [Cited by in Crossref: 122] [Cited by in F6Publishing: 127] [Article Influence: 9.4] [Reference Citation Analysis]
43 Park YY, Choi HS, Lee JS. Systems-level analysis of gene expression data revealed NR0B2/SHP as potential tumor suppressor in human liver cancer. Mol Cells 2010;30:485-91. [PMID: 20853064 DOI: 10.1007/s10059-010-0136-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
44 Dooley S, ten Dijke P. TGF-β in progression of liver disease. Cell Tissue Res. 2012;347:245-256. [PMID: 22006249 DOI: 10.1007/s00441-011-1246-y] [Cited by in Crossref: 409] [Cited by in F6Publishing: 419] [Article Influence: 37.2] [Reference Citation Analysis]
45 Huang W, Gao F, Li K, Wang W, Lai YR, Tang SH, Yang DH. Decaprenyl diphosphate synthase subunit 2 as a prognosis factor in hepatocellular carcinoma. World J Gastroenterol 2015; 21(10): 3055-3065 [PMID: 25780306 DOI: 10.3748/wjg.v21.i10.3055] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
46 Yao DF, Gu WJ, Li YM. Expression and dynamic alteration of hepatoma-related growth factors during malignant transformation of hepatocytes. Shijie Huaren Xiaohua Zazhi 2008; 16(23): 2570-2575 [DOI: 10.11569/wcjd.v16.i23.2570] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Marquardt JU, Thorgeirsson SS. Stem cells in hepatocarcinogenesis: evidence from genomic data. Semin Liver Dis. 2010;30:26-34. [PMID: 20175031 DOI: 10.1055/s-0030-1247130] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 3.1] [Reference Citation Analysis]
48 Raggi C, Invernizzi P, Andersen JB. Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: molecular networks and biological concepts. J Hepatol. 2015;62:198-207. [PMID: 25220250 DOI: 10.1016/j.jhep.2014.09.007] [Cited by in Crossref: 48] [Cited by in F6Publishing: 96] [Article Influence: 6.0] [Reference Citation Analysis]
49 Hevener AL, Febbraio MA; Stock Conference Working Group. The 2009 stock conference report: inflammation, obesity and metabolic disease. Obes Rev 2010;11:635-44. [PMID: 20002885 DOI: 10.1111/j.1467-789X.2009.00691.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
50 Quagliata L, Schlageter M, Quintavalle C, Tornillo L, Terracciano LM. Identification of New Players in Hepatocarcinogenesis: Limits and Opportunities of Using Tissue Microarray (TMA). Microarrays (Basel) 2014;3:91-102. [PMID: 27600338 DOI: 10.3390/microarrays3020091] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
51 Kessler SM, Laggai S, Barghash A, Schultheiss CS, Lederer E, Artl M, Helms V, Haybaeck J, Kiemer AK. IMP2/p62 induces genomic instability and an aggressive hepatocellular carcinoma phenotype. Cell Death Dis 2015;6:e1894. [PMID: 26426686 DOI: 10.1038/cddis.2015.241] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 5.0] [Reference Citation Analysis]
52 Marra M, Sordelli IM, Lombardi A, Lamberti M, Tarantino L, Giudice A, Stiuso P, Abbruzzese A, Sperlongano R, Accardo M. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med. 2011;9:171. [PMID: 21985599 DOI: 10.1186/1479-5876-9-171] [Cited by in Crossref: 143] [Cited by in F6Publishing: 134] [Article Influence: 13.0] [Reference Citation Analysis]
53 Memon A, Pyao Y, Jung Y, Lee JI, Lee WK. A Modified Protocol of Diethylnitrosamine Administration in Mice to Model Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E5461. [PMID: 32751728 DOI: 10.3390/ijms21155461] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
54 Caillot F, Derambure C, Bioulac-Sage P, François A, Scotte M, Goria O, Hiron M, Daveau M, Salier JP. Transient and etiology-related transcription regulation in cirrhosis prior to hepatocellular carcinoma occurrence. World J Gastroenterol 2009; 15(3): 300-309 [PMID: 19140229 DOI: 10.3748/wjg.15.300] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
55 Merle P, Trepo C. Molecular mechanisms underlying hepatocellular carcinoma. Viruses. 2009;1:852-872. [PMID: 21994573 DOI: 10.3390/v1030852] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
56 Calvisi DF, Frau M, Tomasi ML, Feo F, Pascale RM. Deregulation of signalling pathways in prognostic subtypes of hepatocellular carcinoma: novel insights from interspecies comparison. Biochim Biophys Acta 2012;1826:215-37. [PMID: 23393659 DOI: 10.1016/j.bbcan.2012.04.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 21] [Article Influence: 0.6] [Reference Citation Analysis]
57 Frau M, Biasi F, Feo F, Pascale RM. Prognostic markers and putative therapeutic targets for hepatocellular carcinoma. Mol Aspects Med 2010;31:179-93. [PMID: 20176048 DOI: 10.1016/j.mam.2010.02.007] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 4.7] [Reference Citation Analysis]
58 Blum HE. Individualized medicine 2010. J Cell Mol Med 2010;14:2257-63. [PMID: 20731747 DOI: 10.1111/j.1582-4934.2010.01155.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
59 Frau M, Simile MM, Tomasi ML, Demartis MI, Daino L, Seddaiu MA, Brozzetti S, Feo CF, Massarelli G, Solinas G, Feo F, Lee JS, Pascale RM. An expression signature of phenotypic resistance to hepatocellular carcinoma identified by cross-species gene expression analysis. Cell Oncol (Dordr) 2012;35:163-73. [PMID: 22434528 DOI: 10.1007/s13402-011-0067-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
60 Amer M, Elhefnawi M, El-Ahwany E, Awad AF, Gawad NA, Zada S, Tawab FM. Hsa-miR-195 targets PCMT1 in hepatocellular carcinoma that increases tumor life span. Tumour Biol 2014;35:11301-9. [PMID: 25119594 DOI: 10.1007/s13277-014-2445-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
61 Berasain C, Perugorria MJ, Latasa MU, Castillo J, Goñi S, Santamaría M, Prieto J, Avila MA. The epidermal growth factor receptor: a link between inflammation and liver cancer. Exp Biol Med (Maywood) 2009;234:713-25. [PMID: 19429859 DOI: 10.3181/0901-MR-12] [Cited by in Crossref: 88] [Cited by in F6Publishing: 47] [Article Influence: 6.8] [Reference Citation Analysis]
62 Wild CP, Montesano R. A model of interaction: aflatoxins and hepatitis viruses in liver cancer aetiology and prevention. Cancer Lett. 2009;286:22-28. [PMID: 19345001 DOI: 10.1016/j.canlet.2009.02.053] [Cited by in Crossref: 103] [Cited by in F6Publishing: 82] [Article Influence: 7.9] [Reference Citation Analysis]
63 Shi Z, Moult J. Structural and functional impact of cancer-related missense somatic mutations. J Mol Biol 2011;413:495-512. [PMID: 21763698 DOI: 10.1016/j.jmb.2011.06.046] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
64 Youness ER, El Nemr M, Oraby FS, Ahmed NM, Moghni MA, Aly HF, Ahmed HH. Evaluation of Apoptotic Marker Bcl2, CD4+, Human Hepatocyte Growth Factor and Metalloproteinase-9 as Tumor Markers for Patients with Hepatocellular Carcinoma. Indian J Clin Biochem 2014;29:351-6. [PMID: 24966485 DOI: 10.1007/s12291-013-0381-5] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
65 Koch KS, Leffert HL. Hypothesis: Targeted Ikkβ deletion upregulates MIF signaling responsiveness and MHC class II expression in mouse hepatocytes. Hepat Med 2010;2010:39-47. [PMID: 23997575 DOI: 10.2147/HMER.S7208] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
66 Hsu SH, Wang B, Kota J, Yu J, Costinean S, Kutay H, Yu L, Bai S, La Perle K, Chivukula RR, Mao H, Wei M, Clark KR, Mendell JR, Caligiuri MA, Jacob ST, Mendell JT, Ghoshal K. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest. 2012;122:2871-2883. [PMID: 22820288 DOI: 10.1172/jci63539] [Cited by in Crossref: 532] [Cited by in F6Publishing: 329] [Article Influence: 53.2] [Reference Citation Analysis]
67 Zubaidah RM, Tan GS, Tan SBE, Lim SG, Lin Q, Chung MCM. 2-D DIGE profiling of hepatocellular carcinoma tissues identified isoforms of far upstream binding protein (FUBP) as novel candidates in liver carcinogenesis. Proteomics 2008;8:5086-96. [DOI: 10.1002/pmic.200800322] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
68 Dang H, Pomyen Y, Martin SP, Dominguez DA, Yim SY, Lee JS, Budhu A, Shah AP, Bodzin AS, Wang XW. NELFE-Dependent MYC Signature Identifies a Unique Cancer Subtype in Hepatocellular Carcinoma. Sci Rep 2019;9:3369. [PMID: 30833661 DOI: 10.1038/s41598-019-39727-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
69 Bisteau X, Caldez MJ, Kaldis P. The Complex Relationship between Liver Cancer and the Cell Cycle: A Story of Multiple Regulations. Cancers (Basel) 2014;6:79-111. [PMID: 24419005 DOI: 10.3390/cancers6010079] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 5.5] [Reference Citation Analysis]
70 Baddour N, Farrag E, Zeid A, Bedewy E, Taher Y. Decreased apoptosis in advanced-stage/high-grade hepatocellular carcinoma complicating chronic hepatitis C is mediated through the downregulation of p21 ras. Chin J Cancer Res 2013;25:281-8. [PMID: 23825904 DOI: 10.3978/j.issn.1000-9604.2013.04.02] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
71 Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, Brackett DJ, Roberts LR, Schmittgen TD. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res. 2008;14:419-427. [PMID: 18223217 DOI: 10.1158/1087-0432.CCR-07-0523] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
72 Hussain SP, Schwank J, Staib F, Wang XW, Harris CC. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene. 2007;26:2166-2176. [PMID: 17401425 DOI: 10.1038/sj.onc.1210279] [Cited by in Crossref: 369] [Cited by in F6Publishing: 346] [Article Influence: 24.6] [Reference Citation Analysis]
73 Ho DW, Kai AK, Ng IO. TCGA whole-transcriptome sequencing data reveals significantly dysregulated genes and signaling pathways in hepatocellular carcinoma. Front Med 2015;9:322-30. [DOI: 10.1007/s11684-015-0408-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 5.7] [Reference Citation Analysis]
74 Kirovski G, Stevens AP, Czech B, Dettmer K, Weiss TS, Wild P, Hartmann A, Bosserhoff AK, Oefner PJ, Hellerbrand C. Down-regulation of methylthioadenosine phosphorylase (MTAP) induces progression of hepatocellular carcinoma via accumulation of 5'-deoxy-5'-methylthioadenosine (MTA). Am J Pathol 2011;178:1145-52. [PMID: 21356366 DOI: 10.1016/j.ajpath.2010.11.059] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
75 Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, Brackett DJ, Roberts LR, Schmittgen TD. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res. 2008;14:419-427. [PMID: 18223217 DOI: 10.1158/1078-0432.ccr-07-0523] [Cited by in Crossref: 368] [Cited by in F6Publishing: 222] [Article Influence: 26.3] [Reference Citation Analysis]
76 Wang C, Maass T, Krupp M, Thieringer F, Strand S, Wörns MA, Barreiros A, Galle PR, Teufel A. A systems biology perspective on cholangiocellular carcinoma development: Focus on MAPK-signaling and the extracellular environment. Journal of Hepatology 2009;50:1122-31. [DOI: 10.1016/j.jhep.2009.01.024] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
77 Cui JF, Liu YK, Zhou HJ, Kang XN, Huang C, He YF, Tang ZY, Uemura T. Screening serum hepatocellular carcinoma-associated proteins by SELDI-based protein spectrum analysis. World J Gastroenterol 2008; 14(8): 1257-1262 [PMID: 18300354 DOI: 10.3748/wjg.14.1257] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
78 Liu C, Shen J, Pan C, Yang L, Mou S, Wang H, Liang Y. MALDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of boosting decision tree model for diagnosis of hepatocellular carcinoma. Am J Clin Pathol 2010;134:235-41. [PMID: 20660326 DOI: 10.1309/AJCPA6C6NOGFLYIR] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
79 Freimuth J, Gassler N, Moro N, Günther RW, Trautwein C, Liedtke C, Krombach GA. Application of magnetic resonance imaging in transgenic and chemical mouse models of hepatocellular carcinoma. Mol Cancer 2010;9:94. [PMID: 20429921 DOI: 10.1186/1476-4598-9-94] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
80 Su H, Zhao J, Xiong Y, Xu T, Zhou F, Yuan Y, Zhang Y, Zhuang SM. Large-scale analysis of the genetic and epigenetic alterations in hepatocellular carcinoma from Southeast China. Mutat Res. 2008;641:27-35. [PMID: 18358501 DOI: 10.1016/j.mrfmmm.2008.02.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 2.2] [Reference Citation Analysis]
81 Marquardt JU, Factor VM, Thorgeirsson SS. Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications. J Hepatol 2010;53:568-77. [PMID: 20646772 DOI: 10.1016/j.jhep.2010.05.003] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 5.5] [Reference Citation Analysis]